Dirk Reyn
Directeur/Membre du Conseil chez BbyB Chocolates
Provenance du réseau au premier degré de Dirk Reyn
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
19
| Holding Company | Medical Specialties | 19 |
FlandersBio vzw
 FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen.
8
| Private Company | Miscellaneous Commercial Services | 8 |
Progress Pharma NV
 Progress Pharma NV BiotechnologyHealth Technology Progress Pharma NV adopts a business model for asset-centric drug development. The company is headquartered in Vosselaar, Belgium.
1
| Private Company | Biotechnology | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Dirk Reyn via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| RENEURON GROUP PLC | Pharmaceuticals: Major | Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Smeets Securities BV | Corporate Officer/Principal | ||
Novavax AB
 Novavax AB Pharmaceuticals: GenericHealth Technology Novavax AB is engaged in research and development of vaccines. Its products include Matrix and AbiSCO. The company was founded by Bror Morein in 1999 and is headquartered in Uppsala, Sweden. | Pharmaceuticals: Generic | Chief Executive Officer Chief Executive Officer | |
| Massachusetts Institute of Technology | College/University | Graduate Degree | |
| INSEAD | College/University | Masters Business Admin | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
| ABLYNX | Biotechnology | Director/Board Member Director/Board Member Chairman Director/Board Member Corporate Officer/Principal | |
| Instituto de Empresa SL | College/University | Masters Business Admin Graduate Degree | |
| University of Bocconi | College/University | Doctorate Degree | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| Ghent University | College/University | Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Director/Board Member Graduate Degree Undergraduate Degree Doctorate Degree | |
| Vlerick Leuven Gent Management School | College/University | Director/Board Member Masters Business Admin | |
Vlaams Instituut voor Biotechnologie - Flanders Institute
 Vlaams Instituut voor Biotechnologie - Flanders Institute Other Consumer ServicesConsumer Services Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium. | College/University | Corporate Officer/Principal Director/Board Member | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Chairman Director of Finance/CFO Chief Tech/Sci/R&D Officer Director/Board Member | |
| Université Catholique de Louvain | College/University | Chairman Graduate Degree Corporate Officer/Principal Corporate Officer/Principal Graduate Degree | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Founder Private Equity Investor | |
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
Vesalius Biocapital I SA SICAR
 Vesalius Biocapital I SA SICAR Investment ManagersFinance Vesalius Biocapital I SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Investment Managers | Chairman Director/Board Member | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Chairman | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director of Finance/CFO | |
SPV 162
 SPV 162 Engineering & ConstructionIndustrial Services Part of SNCB/NMBS, SPV 162 constructs roads and motorways. The company is based in Saint-Gilles, Belgium. The CEO of the Belgian company is Christine Vanderveeren. | Engineering & Construction | Director/Board Member | |
| Hogeschool-Universiteit Brussel | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
KBC Global Services NV
 KBC Global Services NV Regional BanksFinance Part of KBC Group NV, KBC Global Services NV provides banking and wealth management services. The company is based in Sint-Jans-Molenbeek, Belgium. | Regional Banks | Director/Board Member | |
KBC Assurances SA
 KBC Assurances SA Multi-Line InsuranceFinance KBC Assurances SA is a Belgian insurance company that provides insurance services. The private company is based in Leuven, Belgium. The company was founded in 1922. | Multi-Line Insurance | Director/Board Member | |
Leuven.Inc Vzw
 Leuven.Inc Vzw Miscellaneous Commercial ServicesCommercial Services Leuven.Inc Vzw provides administration and management consulting services. The company was founded by Imec, Arthur Andersen and Fortis Bank in 1999 and is headquartered in Leuven, Belgium. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| University of Antwerp | College/University | Graduate Degree Doctorate Degree | |
Vesalius Biocapital II SA SICAR
 Vesalius Biocapital II SA SICAR Investment ManagersFinance Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Investment Managers | Chairman Director/Board Member | |
Gri-Cel SA
 Gri-Cel SA Financial ConglomeratesFinance Part of Grifols SA, Gri-Cel SA provides investment services. The company is based in Barcelona, Spain. The CEO of the Spanish company is Dirk Büscher. | Financial Conglomerates | Chief Executive Officer Chief Operating Officer | |
| BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Chairman | |
VCN Biosciences SL
 VCN Biosciences SL Miscellaneous Commercial ServicesCommercial Services Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| BIOTALYS NV | Chemicals: Agricultural | Director/Board Member Director/Board Member | |
LUCA School of Arts VZW
 LUCA School of Arts VZW Other Consumer ServicesConsumer Services LUCA School of Arts VZW is an institution that offers a product design course that teaches students to become designers who can improve the world in various ways. LUCA School of Arts is located in Genk, Ghent, and Leuven, Belgium. The course covers designing solutions, expressing oneself critically, designing with the user in mind, and shedding light on societal and individual problems. The institution also offers a program that trains students to become authors or autonomous illustrators in fiction and non-fiction. The institution is committed to research and innovation, which plays a significant role in its curriculum. LUCA School of Arts collaborates with small and medium-sized organizations to develop innovative solutions to real-world problems. Simon van Damme has been the CEO of the Belgian company since 2018. | Other Consumer Services | Director/Board Member | |
Vlaamse Universiteiten & Hogescholen Raad VZW
 Vlaamse Universiteiten & Hogescholen Raad VZW Miscellaneous Commercial ServicesCommercial Services Vlaamse Universiteiten & Hogescholen Raad VZW is a council that oversees universities and colleges in Flanders, Belgium. The council was founded in 2010 and is based in Brussels, Belgium. The Belgian company's website provides information about their assignment, administrative bodies, annual reports, and contact details of employees. Additionally, they offer an overview of the projects they have supported. The website is available in both Dutch and English. | Miscellaneous Commercial Services | Director/Board Member |
Statistiques
Internationale
| Belgique | 28 |
| Espagne | 7 |
| Etats-Unis | 4 |
| Pays-Bas | 3 |
| Royaume-Uni | 3 |
Sectorielle
| Health Technology | 18 |
| Consumer Services | 12 |
| Finance | 9 |
| Commercial Services | 7 |
| Consumer Non-Durables | 2 |
Opérationnelle
| Director/Board Member | 224 |
| Chairman | 63 |
| Corporate Officer/Principal | 59 |
| Independent Dir/Board Member | 31 |
| Chief Executive Officer | 28 |
Relations les plus connectées
| Insiders | |
|---|---|
| Koenraad Debackere | 48 |
| Baron Jean Stéphenne | 36 |
| Russell Greig | 31 |
| Patrick van Beneden | 28 |
| Mounia Chaoui-Roulleau | 27 |
| Sven Arne Andréasson | 24 |
| Jim van Heusden | 22 |
| Ruth Devenyns | 18 |
| Gil Beyen | 18 |
| Joël Jean-Mairet | 17 |
| Nico Vandervelpen | 17 |
| Herman Verrelst | 16 |
| Marie Paule Richard | 15 |
| Chris de Jonghe | 15 |
| June Almenoff | 14 |
